Alexandria Cogdill

Alexandria “Alex” Cogdill, MEng, PhD, is a biopharma executive and corporate strategist focused on external innovation, global business development, and enterprise strategy. She brings nearly two decades of experience spanning drug development, venture creation, and global pharma. She currently serves as Head of Strategic Initiatives within Global Business Development at Daiichi Sankyo, where she works at the intersection of science, capital, and the systems shaping drug development.

Dr. Cogdill has helped shape development decisions, platform strategies, and AI enabled R&D partnerships contributing to billions in aggregate deal value. She trained under Nobel laureate Jim Allison and contributed to translational research during the development of the first CD19 CAR-T therapy with Carl June. Her career has spanned leading institutions such as the National Institutes of Health, Harvard University, the University of Pennsylvania, Institut Gustave Roussy, and Flagship Pioneering. She has authored more than 65 peer reviewed publications, with over 28,000 citations, with notable work in Nature, Science, and Cell.

Alex holds a PhD in Immunology from The University of Texas MD Anderson Cancer Center, an MEng in Bioengineering and Entrepreneurship from the University of Pennsylvania, and a BSc in Molecular Biology from the University of North Carolina, Pembroke. She is currently pursuing an Executive MBA at MIT Sloan as a member of the Class of 2028.